Clinical Trials in San Antonio

Showing 5181-5200 of 14,633 trials

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma

NCT02314052

The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene MYC. MYC oncogene activation is important to the growth of many hematologic and solid tumor malignancies. In this study the Sponsor proposes to study DCR-MYC and its ability to inhibit MYC and thereby inhibit cancer cell growth.

Hepatocellular Carcinoma

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company21 participantsStarted Jan 2015

Scottsdale, Arizona, United States • Boston, Massachusetts, United States • San Antonio, Texas, United States +3 more locations

COMPLETEDPhase 1< 1 mile

Study of ASN004 in Patients With Advanced Solid Tumors

NCT04410224

Participants in this study will receive ASN004 once every 3 or 4 weeks by intravenous infusion. The ASN004 dosing schedule may be modified based on emerging data and Safety Review Committee decision. The study will test various doses of ASN004 to find out the highest safe dose to test in future trials. Eligible subjects will be sequentially enrolled in cohorts at escalated doses.

Solid Tumor

Kirilys Therapeutics Inc.19 participantsStarted Apr 2022

Atlanta, Georgia, United States • Austin, Texas, United States • San Antonio, Texas, United States +1 more locations

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma

Study of ASN004 in Patients With Advanced Solid Tumors

Find Trials by Condition in San Antonio

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access Grafts

Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)

Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

TARGET Post-Approval Study

Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders

Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization

Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop

A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)

Ambispective Clinical Evaluation of Sophono™

Vibrant Capsule vs. Placebo for Patient Suffering From Constipation